Research to develop the gel sold today under the Wound-Be-Gone® brand name began in the first half of the 1990s. However, the research at the time would not have been possible without earlier studies by the Institute of Macromolecular Chemistry of the Academy of Science of the Czech Republic.Wound-Be-Gone® owes its existence to the discovery of hydrophilic polymers based on poly (2-hydroxyethyl methacrylate). This discovery by Professor Wichterle and his team is the basis of the chemical composition used to create Wound-Be-Gone®.The research team made a major breakthrough in the mid-1990s when it began to realize the idea of Jiri Labsky, Ph.D, who integrated sterically hindered amines, so-called “free radical traps,” into specific polymers that the human body can recognize. Free radicals, which are created in abundance during tissue damage, react with these amines or with their oxidation derivatives. This reaction neutralizes free radicals, thus preventing their otherwise aggressive impact on the body.The use of polymer matrices has a number of advantages. They are composed of large macromolecules which are interconnected. This prevents the molecules from penetrating the skin and invading the body. Thus, they remain on the wound’s surface. This allows our active ingredient to work undisturbed.
In 1997, the invention received a Czech patent, but the process of developing an accessible product was far from over. Transferring laboratory results into a format that could work in large-scale production was very difficult. The research team had to answer a number of questions in order to optimize the chemical structure. This range of problems brought a need to find balance between the product’s effectiveness and its cost, i.e., viable mass production.
The Institute of Macromolecular Chemistry of the Academy of Sciences of the Czech Republic is the patent-holder. The Institute has granted rights for manufacturing the product (sold under the registered trademark, Wound-Be-Gone®) to Wake Pharma US, Inc. based on an exclusive contract. Wake Pharma Ltd. and Wake Pharma US, Inc. have exclusive sales and marketing rights for the product.